Premium Nahrungsergänzungsmittel | artgerecht

Akkermansia muciniphila: Gut Health & Microbiome

Akkermansia muciniphila is a gut bacterium that strengthens the intestinal barrier and supports metabolic health. It is considered a key component of a healthy gut microbiome.

Regular tips about health Regular tips about health

Things worth knowing about "Akkermansia"

Akkermansia muciniphila is a gut bacterium that strengthens the intestinal barrier and supports metabolic health. It is considered a key component of a healthy gut microbiome.

What is Akkermansia?

Akkermansia muciniphila is a gram-negative bacterium that naturally inhabits the human gut. It belongs to the phylum Verrucomicrobia and was first scientifically described in 2004. The bacterium colonizes the mucus layer of the large intestine and plays a central role in maintaining intestinal barrier integrity as well as various metabolic processes.

Biological Function and Mechanism of Action

Akkermansia muciniphila primarily feeds on mucin, the main component of the intestinal mucus layer. During this process, it produces short-chain fatty acids (particularly acetate and propionate), which serve as an energy source for intestinal cells and exert anti-inflammatory effects.

Strengthening the intestinal barrier: The bacterium promotes mucin production and increases the density of tight junctions -- specialized cell connections that prevent harmful substances from leaking from the gut into the bloodstream.
Metabolic regulation: Studies show that higher levels of Akkermansia are associated with improved blood sugar management and lower body weight.
Immune modulation: The bacterium positively influences the immune system by dampening excessive inflammatory responses.

Health Significance

Numerous clinical and preclinical studies have identified links between low Akkermansia levels and various health conditions:

Metabolic syndrome and type 2 diabetes: Individuals with obesity or insulin resistance often show reduced Akkermansia concentrations in the gut.
Inflammatory bowel disease: Reduced Akkermansia levels have been observed in patients with Crohn's disease and ulcerative colitis.
Cardiovascular disease: Diminished Akkermansia colonization is also associated with cardiovascular risk factors.
Cancer therapy: Emerging research suggests that Akkermansia may enhance the efficacy of immune checkpoint inhibitors, a form of cancer immunotherapy.

How to Promote Akkermansia Growth

The concentration of Akkermansia muciniphila in the gut can be positively influenced through targeted dietary and lifestyle measures:

High-fiber diet: Prebiotic fibers from vegetables, legumes, and whole grains promote the growth of Akkermansia.
Polyphenols: Plant-based bioactive compounds found in berries, green tea, pomegranate, and dark chocolate can support Akkermansia populations.
Omega-3 fatty acids: Found in fatty fish and flaxseed products; support a balanced microbiome.
Caloric restriction and intermittent fasting: Studies suggest that these strategies can increase the proportion of Akkermansia in the gut.
Akkermansia supplements: Pasteurized Akkermansia muciniphila preparations are available as dietary supplements in the EU and have been assessed as safe and effective in clinical studies.

Safety and Dosage

Pasteurized Akkermansia supplements are considered well-tolerated according to current studies. The European Food Safety Authority (EFSA) has approved the use of pasteurized Akkermansia muciniphila as a novel food. Typical dosages used in clinical studies range from 10⁹ to 10¹⁰ colony-forming units (CFU) per day. Individuals with severely compromised immune systems should only take this supplement under medical supervision.

References

Plovier H et al. (2017): A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine, 23(1), 107-113.
Depommier C et al. (2019): Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine, 25(7), 1096-1103.
European Food Safety Authority (EFSA) (2021): Safety of pasteurised Akkermansia muciniphila as a novel food. EFSA Journal, 19(9), e06780.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.